Skip to main content
Equibles
TVTX logo

TVTX · Travere Therapeutics, Inc.

Track TVTX — free

Use TVTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$65.28 -1.26 (-1.89%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$6.15B
Shares
94.26M

TVTX metrics

65 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$65.28
Market cap
$6.15B

Price action

19 metrics
Price change (1W)
-0.6%
Price change (30D)
+7.2%
Price change (3M)
+42.5%
Price change (6M)
+139.6%
Price change (YTD)
+70.8%
Price change (1Y)
+208.7%
Trailing year
Price change (5Y)
+208.9%
52-week high
$67.52
52-week low
$21.15
Change from 52-week high
-3.3%
Change from 52-week low
+208.7%
Annualized volatility
70.8%
Beta
1.5
RSI (14D)
56.6
Price vs SMA 50
+8.3%
Price vs SMA 200
+53.9%
Avg volume (3M)
1.74M
Relative volume
0.6
Average dollar volume
$100.83M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
94.26M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
10.4×
reciprocal yield 9.6%
P / book
250.9
reciprocal yield 0.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
66.4
reciprocal yield 1.5%
Earnings yield
-0.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
98.6%
Operating margin
-6.8%
Trailing 12 months
Net margin
-7.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$40.46M
Net income (TTM)
−$43.46M
Trailing 12 months
Diluted EPS (TTM)
$-0.45
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.30

Growth

11 metrics
Revenue growth YoY
+48.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$591.33M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.1%
Year over year · more shares
Revenue CAGR (3Y)
+64.9%
Revenue CAGR (5Y)
+19.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-177.2%
Return on assets
-5.4%
Debt / equity
—
Current ratio
4.0
EBITDA (TTM)
$22.91M
Free cash flow (TTM)
—
Quick ratio
3.8
Interest coverage
-4.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$117.73M
Total assets
$799.36M
Total debt
$46.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$92.70M
Capital expenditures (TTM)
$107,000
R&D (TTM)
$227.14M
SG&A (TTM)
$390.57M
Stock compensation (TTM)
$60.66M
R&D / revenue
38.4%
Stock compensation / revenue
10.3%

Ownership (13F)

3 metrics
13F filers
320
13F filer change QoQ
+55
Institutional ownership
113.7%

Short interest

3 metrics
Short interest
12.7%
Latest settlement · 5.7 days to cover
Days to cover
5.7d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.40M
Insider-sentiment score
58 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1438533 CUSIP 89422G107 13F (30d) 214 filings 213 filers Visit website Investor relations